• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

观察性研究中分析治疗效果时的“不朽时间”问题。

Issues regarding 'immortal time' in the analysis of the treatment effects in observational studies.

机构信息

United States Renal Data System, Minneapolis Medical Research Foundation, Minneapolis, Minnesota 55404, USA.

出版信息

Kidney Int. 2012 Feb;81(4):341-50. doi: 10.1038/ki.2011.388. Epub 2011 Nov 16.

DOI:10.1038/ki.2011.388
PMID:22089946
Abstract

In observational studies, treatment is often time dependent. Mishandling the time from the beginning of follow-up to treatment initiation can result in bias known as immortal time bias. Nephrology researchers who conduct observational research must be aware of how immortal time bias can be introduced into analyses. We review immortal time bias issues in time-to-event analyses in the biomedical literature and give examples from the nephrology literature. We also use simulations to quantify the bias in different methods of mishandling immortal time; intuitively explain how bias is introduced when immortal time is mishandled; raise issues regarding unadjusted treatment comparison, patient characteristics comparison, and confounder adjustment; and, using data from DaVita Inc., linked with the Centers for Medicare & Medicaid Services end-stage renal disease database, show that the severity of bias and the issues described can occur in actual data analyses of patients with end-stage renal disease. In the simulation examples, mishandling immortal time led to an underestimated hazard ratio (treatment vs. control), thus an overestimated treatment effect, by as much as 96%, and an overestimated hazard ratio by as much as 138%, depending on the distribution of 'survival' time and the method used. Results from the DaVita data were consistent with the simulation. Careful consideration of methodology is needed in observational analyses with time-dependent treatment.

摘要

在观察性研究中,治疗通常是时间依赖性的。如果在开始随访到开始治疗的时间处理不当,可能会导致一种称为不朽时间偏差的偏差。进行观察性研究的肾脏病学研究人员必须意识到如何在分析中引入不朽时间偏差。我们回顾了生物医学文献中事件时间分析中的不朽时间偏差问题,并从肾脏病学文献中举例说明。我们还使用模拟来量化不同处理不朽时间不当方法的偏差;直观地解释了当不朽时间处理不当时如何引入偏差;提出关于未调整治疗比较、患者特征比较和混杂因素调整的问题;并使用来自 DaVita Inc. 的数据,与医疗保险和医疗补助服务中心的终末期肾病数据库相关联,表明严重程度偏差和描述的问题可能会出现在终末期肾病患者的实际数据分析中。在模拟示例中,处理不朽时间不当会导致风险比(治疗与对照)低估,从而治疗效果高估,最大可达 96%,风险比高估最大可达 138%,具体取决于“生存”时间的分布和使用的方法。DaVita 数据的结果与模拟结果一致。在时间依赖性治疗的观察性分析中需要仔细考虑方法学。

相似文献

1
Issues regarding 'immortal time' in the analysis of the treatment effects in observational studies.观察性研究中分析治疗效果时的“不朽时间”问题。
Kidney Int. 2012 Feb;81(4):341-50. doi: 10.1038/ki.2011.388. Epub 2011 Nov 16.
2
Immortal time bias in pharmaco-epidemiology.药物流行病学中的不朽时间偏倚。
Am J Epidemiol. 2008 Feb 15;167(4):492-9. doi: 10.1093/aje/kwm324. Epub 2007 Dec 3.
3
Immortal time bias in drug safety cohort studies: spontaneous abortion following nonsteroidal antiinflammatory drug exposure.药物安全性队列研究中的不朽时间偏倚:非甾体抗炎药暴露后的自然流产。
Am J Obstet Gynecol. 2015 Mar;212(3):307.e1-6. doi: 10.1016/j.ajog.2014.09.028. Epub 2014 Oct 12.
4
Inhaled corticosteroids in chronic obstructive pulmonary disease: results from two observational designs free of immortal time bias.慢性阻塞性肺疾病中吸入性糖皮质激素:两项无不朽时间偏倚的观察性研究结果
Am J Respir Crit Care Med. 2005 Aug 15;172(4):460-4. doi: 10.1164/rccm.200502-210OC. Epub 2005 May 18.
5
Implications of immortal person-time when outcomes are nonfatal.当结局不是致命时,不朽的人时的影响。
Ann Epidemiol. 2016 Mar;26(3):212-7. doi: 10.1016/j.annepidem.2015.12.004. Epub 2016 Jan 12.
6
Comparison of Statistical Approaches for Dealing With Immortal Time Bias in Drug Effectiveness Studies.药物有效性研究中处理不朽时间偏倚的统计方法比较。
Am J Epidemiol. 2016 Aug 15;184(4):325-35. doi: 10.1093/aje/kwv445. Epub 2016 Jul 25.
7
Use of the landmark method to address immortal person-time bias in comparative effectiveness research: a simulation study.使用地标法解决比较效果研究中的不朽人时偏倚:一项模拟研究。
Stat Med. 2016 Nov 20;35(26):4824-4836. doi: 10.1002/sim.7019. Epub 2016 Jun 27.
8
Understanding and Avoiding Immortal-Time Bias in Gastrointestinal Observational Research.理解并避免胃肠病观察性研究中的不朽时间偏倚
Am J Gastroenterol. 2015 Dec;110(12):1647-50. doi: 10.1038/ajg.2015.210. Epub 2015 Sep 1.
9
Estimating the effect of immortal-time bias in urological research: a case example of testosterone-replacement therapy.评估泌尿外科研究中永生时间偏倚的影响:睾酮替代疗法的一个实例
BJU Int. 2017 Oct;120(4):584-590. doi: 10.1111/bju.13918. Epub 2017 Jun 18.
10
Duration of antidepressant drug treatment and its influence on risk of relapse/recurrence: immortal and neglected time bias.抗抑郁药物治疗的持续时间及其对复发风险的影响:不朽且被忽视的时间偏倚。
Am J Epidemiol. 2009 Aug 1;170(3):280-5. doi: 10.1093/aje/kwp142. Epub 2009 Jun 4.

引用本文的文献

1
Variability of quality-of-life measurements and reporting in randomised controlled trials of pancreatic cancer: a systematic review.胰腺癌随机对照试验中生活质量测量和报告的变异性:系统评价。
BMJ Open. 2024 Nov 17;14(11):e083696. doi: 10.1136/bmjopen-2023-083696.
2
Early Anuria in Incident Peritoneal Dialysis Patients: Incidence, Risk Factors, and Associated Clinical Outcomes.新发腹膜透析患者的早期无尿:发生率、危险因素及相关临床结局
Kidney Med. 2024 Jul 25;6(10):100882. doi: 10.1016/j.xkme.2024.100882. eCollection 2024 Oct.
3
The Controversies of Coronary Artery Disease in End-Stage Kidney Disease Patients: A Narrative Review.
终末期肾病患者冠状动脉疾病的争议:一项叙述性综述
Rev Cardiovasc Med. 2023 Jun 25;24(6):181. doi: 10.31083/j.rcm2406181. eCollection 2023 Jun.
4
Methodological biases in observational hospital studies of COVID-19 treatment effectiveness: pitfalls and potential.COVID-19治疗效果的观察性医院研究中的方法学偏倚:陷阱与潜力
Front Med (Lausanne). 2024 Mar 21;11:1362192. doi: 10.3389/fmed.2024.1362192. eCollection 2024.
5
Comparing broad and narrow phenotype algorithms: differences in performance characteristics and immortal time incurred.比较宽表型和窄表型算法:性能特征差异和所导致的永恒时间。
J Pharm Pharm Sci. 2024 Jan 3;26:12095. doi: 10.3389/jpps.2023.12095. eCollection 2023.
6
The Use of Putative Dialysis Initiation Time in Comparative Outcomes of Patients with Advanced Chronic Kidney Disease: Methodological Aspects.在晚期慢性肾脏病患者比较结局中使用假定透析起始时间:方法学方面
Int J Stat Med Res. 2022;11:128-135. doi: 10.6000/1929-6029.2022.11.16.
7
The incidence of cancer-associated thrombosis is increasing over time.癌症相关血栓形成的发病率随时间推移而增加。
Blood Adv. 2022 Jan 11;6(1):307-320. doi: 10.1182/bloodadvances.2021005590.
8
Returning to dialysis after kidney allograft loss: conflicting survival benefit beyond transplant-naïve maintenance dialysis patients.肾移植失败后重新开始透析:对于非初次接受维持性透析的患者而言,生存获益存在矛盾。
J Nephrol. 2022 Jan;35(1):91-94. doi: 10.1007/s40620-021-01084-0.
9
Survival Benefit of Liver Transplantation for Hepatocellular Carcinoma.肝移植治疗肝细胞癌的生存获益。
Transplantation. 2020 Jan;104(1):104-112. doi: 10.1097/TP.0000000000002816.
10
Association between NSAID use and mortality risk in patients with end-stage renal disease: a population-based cohort study.非甾体抗炎药使用与终末期肾病患者死亡风险之间的关联:一项基于人群的队列研究。
Clin Epidemiol. 2019 May 31;11:429-441. doi: 10.2147/CLEP.S204322. eCollection 2019.